← Research index · Disorder page · Source YAML

Cross-provider research synthesis

BRCA Mutant Prostate Cancer

MONDO:0008315 Curated 2026-07-04T00:00:00Z 8 harmonized findings

falcon · 53 citations openscientist · 53 citations

Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

BRCA-mutant prostate cancer is driven by loss of BRCA1/BRCA2 homologous recombination repair function (HRD), which creates the therapeutic vulnerability exploited by PARP inhibitors through synthetic lethality: PARP inhibition converts unrepaired single-strand breaks into double-strand breaks that HR-deficient cells cannot repair.

UNANIMOUS INTEGRATED

pathophysiologygene_functiontreatment

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	replication forks collapse, and the cell cannot repair the damage (synthetic lethality) Falcon spells out the SSB-to-DSB conversion and replication-fork collapse that underlies synthetic lethality in BRCA1/2-deficient cells. DOI:10.3390/cancers15092662
openscientist	CONCORDANT	95%	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in HR-deficient tumor cells OpenScientist states the same synthetic-lethality mechanism and names the class of PARP inhibitors that exploit it.

BRCA2 is the dominant altered gene in prostate cancer, more common and conferring higher risk than BRCA1.

UNANIMOUS INTEGRATED

genetic_factorepidemiology

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	BRCA2 is the dominant altered gene in prostate cancer and is more common than BRCA1 Falcon asserts BRCA2 predominance over BRCA1 in prostate cancer.
openscientist	CONCORDANT	95%	confer a higher relative risk (~3.6–8.6-fold) than BRCA1 mutations (~1.7-fold) OpenScientist adds quantitative relative-risk estimates showing BRCA2 confers substantially higher risk than BRCA1. PMID:41776557, PMID:24389137

BRCA alterations (particularly BRCA2) define an aggressive prostate cancer subtype with higher-grade disease, earlier onset, and significantly worse survival than non-carriers.

UNANIMOUS INTEGRATED

phenotypeprognosis

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	BRCA alterations—particularly BRCA2—are associated with aggressive disease features and poorer outcomes Falcon links BRCA (especially BRCA2) alterations to aggressive features and poorer outcomes in advanced cohorts.
openscientist	CONCORDANT	95%	The disease is consistently characterized by earlier onset, higher Gleason grades, more aggressive clinical behavior, and significantly worse outcomes compared to non-BRCA sporadic prostate cancers, with 10-year metastasis-free survival of only 50% versus 84% in noncarriers (p < 0.001). OpenScientist quantifies the aggressive phenotype and the survival gap (10-year MFS 50% vs 84%). PMID:25454609

PARP inhibitors (notably olaparib) produce large radiographic progression-free and overall survival benefit in BRCA-mutant mCRPC, making BRCA status a predictive biomarker of PARP inhibitor benefit.

UNANIMOUS INTEGRATED

treatmentprognosis

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	In PROfound BRCA subgroup analysis, olaparib improved rPFS and OS versus control, supporting BRCA alterations as predictive biomarkers of PARP inhibitor benefit Falcon reports the PROfound BRCA-subgroup benefit and frames BRCA as a predictive biomarker. DOI:10.1200/JCO.23.00339
openscientist	CONCORDANT	90%	The PROfound and PROpel trials established olaparib as a transformative therapy OpenScientist likewise anchors olaparib efficacy in the PROfound and PROpel trials. PMID:40397306

Reciprocal AR-PARP crosstalk (AR inhibition downregulating HRR genes and PARP inhibition suppressing AR transcriptional activity) provides the mechanistic rationale for combining PARP inhibitors with AR pathway inhibitors as first-line mCRPC therapy.

MAJORITY INTEGRATED

pathophysiologytreatment

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	AR inhibition downregulates HRR genes and PARP inhibition suppresses AR transcriptional activity Falcon states the bidirectional AR-PARP crosstalk that motivates combination therapy (TALAPRO-2, MAGNITUDE). DOI:10.1038/s41591-023-02704-x
openscientist	PARTIAL	50%	ARPIs (abiraterone, enzalutamide) used both alone and in combination with PARP inhibitors OpenScientist documents PARP-inhibitor/ARPI combination use clinically but does not articulate the molecular AR-PARP crosstalk rationale, so it supports the practice without the mechanism.

Acquired resistance to PARP inhibitors in BRCA-mutant prostate cancer is dominated by BRCA reversion mutations that restore homologous recombination function.

SINGLE INTEGRATED

pathophysiologytreatment

Provider	Stance	Score	Evidence
openscientist	CONCORDANT	95%	Reversion mutations restoring BRCA function are the dominant acquired resistance mechanism OpenScientist devotes a detailed resistance section to BRCA reversion mutations (39-79% prevalence, POLQ-mediated), the dominant acquired resistance mechanism. PMID:36243543, PMID:39577422
falcon	SILENT	—	Falcon does not discuss acquired resistance or BRCA reversion mutations at all (the term does not appear in its report).

Homologous recombination repair gene alterations, led by BRCA2, are enriched in metastatic disease, affecting roughly 20-30% of metastatic prostate cancer overall (with somatic BRCA alterations exceeding germline).

UNANIMOUS LEAD

epidemiologygenetic_factor

Provider	Stance	Score	Evidence
falcon	CONCORDANT	80%	Somatic BRCA alterations are more common than germline across settings, and BRCA2 predominates, with higher frequencies in metastatic disease Falcon reports the Valsecchi meta-analytic BRCA1/2 frequencies by stage, emphasizing somatic > germline and enrichment in metastatic disease. DOI:10.3390/cancers15092435
openscientist	CONCORDANT	80%	affect approximately 20–30% of metastatic prostate cancer patients, with BRCA2 as the most commonly altered gene across diverse global populations. OpenScientist frames the same enrichment through the broader HRR gene set (~20-30% of metastatic disease) with BRCA2 the most common gene, a wider lens than Falcon's BRCA-specific stage-stratified frequencies. PMID:35944490

Male BRCA (especially BRCA2) carriers warrant targeted early PSA-based screening, following the IMPACT-trial protocol of annual PSA testing with a 3.0 ng/mL biopsy threshold beginning at age 40.

UNANIMOUS LEAD

diagnosis

Provider	Stance	Score	Evidence
falcon	CONCORDANT	85%	Annual PSA screening; biopsy threshold PSA >3.0 ng/mL Falcon summarizes the IMPACT-informed screening protocol (annual PSA, >3.0 ng/mL biopsy threshold) for BRCA2 carriers. PMID:38036087
openscientist	CONCORDANT	90%	Annual PSA screening beginning at age 40 for BRCA1/BRCA2 carriers OpenScientist specifies the age-40 start of annual PSA screening for BRCA1/BRCA2 carriers per the IMPACT study. PMID:41714267

Narrative

Overview

Both providers model BRCA-mutant prostate cancer as a molecularly defined prostate cancer subset driven by BRCA1/BRCA2 homologous recombination repair deficiency, with BRCA2 the dominant and more clinically important driver. They agree HRR loss produces genomic instability and aggressive metastatic behavior while simultaneously creating therapeutic sensitivity to PARP inhibition and platinum chemotherapy through synthetic lethality.

Agreement

The two reports converge on the core driver biology (biallelic BRCA loss to HRD), BRCA2 predominance over BRCA1, the aggressive phenotype and worse survival of carriers, the synthetic-lethality rationale and large PARP inhibitor benefit in BRCA-mutant mCRPC (PROfound olaparib rPFS HR 0.22), the move to first-line PARP-inhibitor plus AR-pathway-inhibitor combinations, and IMPACT-informed early PSA screening of male carriers from age 40.

Divergence

Falcon emphasized clinical implementation and diagnostics: PROfound, MAGNITUDE, TALAPRO-2, the AR-PARP crosstalk rationale, tissue-versus-ctDNA testing concordance (with structural-variant blind spots), and MRI/PSA screening pathways. OpenScientist emphasized resistance biology and longitudinal disease behavior; its strongest unique contribution is the acquired-resistance section on BRCA reversion mutations (39-79% prevalence, POLQ-mediated microhomology repair) and serial ctDNA monitoring, a topic on which Falcon is entirely silent. On the AR-PARP combination, OpenScientist documents the clinical practice but not the molecular crosstalk mechanism that Falcon supplies. No direct contradictions were found; divergence is coverage and emphasis, plus a difference in epidemiologic lens (Falcon's BRCA-specific stage-stratified frequencies vs OpenScientist's broader ~20-30% HRR framing).

Integration

Promoted into kb/disorders/BRCA_Mutant_Prostate_Cancer.yaml: HGNC-backed gene_term annotations for BRCA1 and BRCA2; the HRD/synthetic-lethality mechanism; a PARP-Androgen Receptor co-dependency node capturing the AR-PARP crosstalk rationale for combination therapy; a BRCA reversion-mediated PARP resistance node; and a PARP-inhibitor/AR-pathway-inhibitor combination treatment with talazoparib, enzalutamide, niraparib, and abiraterone agents, with Falcon and OpenScientist citation trails recorded as provenance.

Not integrated (leads)

Retained as research leads rather than promoted: detailed trial subgroup tables, exploratory POLQ-inhibitor strategies, full ctDNA/tissue monitoring protocols and structural-variant concordance metrics, broad HRR-gene epidemiology, and non-BRCA HRR genes. These are useful provenance, but the entry is BRCA-focused and should not become a general HRR-mutated prostate cancer entry.

Cross-provider synthesis of two independent deep-research reports: falcon (clinical-implementation and diagnostics emphasis) and openscientist (resistance-biology and comprehensive emphasis). No direct contradictions were found; the principal divergence is coverage (openscientist adds BRCA reversion resistance that falcon omits) and one PARTIAL stance (openscientist documents PARP/ARPI combinations without the AR-PARP crosstalk mechanism). All best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets were intentionally left unpopulated pending fetch-reference verification of the underlying PMIDs/DOIs.